Paper42011199
Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy.
Cheng Q and 6 others. Bioact Mater, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy. Papers, record 42011199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42011199
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36229606 | Metabolic communication in the tumour-immune microenvironment. | Nat Cell Biol | 2022 | https://conductscience.org/library/papers/36229606 | PubMed |
| 2 | 37436776 | Engineered Living Materials for Advanced Diseases Therapy. | Adv Mater | 2025 | https://conductscience.org/library/papers/37436776 | PubMed |
| 3 | 37536496 | L-Arginine self-delivery supramolecular nanodrug for NO gas therapy. | Acta Biomater | 2023 | https://conductscience.org/library/papers/37536496 | PubMed |
| 4 | 35120665 | Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. | Cell | 2022 | https://conductscience.org/library/papers/35120665 | PubMed |
| 5 | 26359979 | Nutrient Competition: A New Axis of Tumor Immunosuppression. | Cell | 2015 | https://conductscience.org/library/papers/26359979 | PubMed |
| 6 | 37046001 | Dynamics and specificities of T cells in cancer immunotherapy. | Nat Rev Cancer | 2023 | https://conductscience.org/library/papers/37046001 | PubMed |
| 7 | 33837297 | Systemic immunity in cancer. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/33837297 | PubMed |
| 8 | 39739630 | Nano-Armed Limosilactobacillus reuteri for Enhanced Photo-Immunotherapy and Microbiota Tryptophan Metabolism against Colorectal Cancer. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39739630 | PubMed |
| 9 | 33177494 | Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/33177494 | PubMed |
| 10 | 28159861 | Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. | Cancer Res | 2017 | https://conductscience.org/library/papers/28159861 | PubMed |
| 11 | 26321679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 12 | 27745970 | L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. | Cell | 2016 | https://conductscience.org/library/papers/27745970 | PubMed |
| 13 | 39558532 | Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective. | J Med Chem | 2024 | https://conductscience.org/library/papers/39558532 | PubMed |
| 14 | 35850444 | Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35850444 | PubMed |
| 15 | 38602715 | Metal-Drug Coordination Nanoparticles and Hydrogels for Enhanced Delivery. | Adv Mater | 2024 | https://conductscience.org/library/papers/38602715 | PubMed |
| 16 | 35968927 | Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response. | ACS Nano | 2022 | https://conductscience.org/library/papers/35968927 | PubMed |
| 17 | 35367839 | LncRNA-targeting bio-scaffold mediates triple immune effects for postoperative colorectal cancer immunotherapy. | Biomaterials | 2022 | https://conductscience.org/library/papers/35367839 | PubMed |
| 18 | 37205768 | PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. | Sci Immunol | 2023 | https://conductscience.org/library/papers/37205768 | PubMed |
| 19 | 29449659 | Using immunotherapy to boost the abscopal effect. | Nat Rev Cancer | 2018 | https://conductscience.org/library/papers/29449659 | PubMed |
| 20 | 27355859 | Synthesis of Monocrystalline Nanoframes of Prussian Blue Analogues by Controlled Preferential Etching. | Angew Chem Int Ed Engl | 2016 | https://conductscience.org/library/papers/27355859 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42011199
GET https://conductscience.org/api/papers/v1/42011199/references?page=2